Lifecore Biomedical Lands New Biopharma Customer for Ophthalmic Injectable Manufacturing
LFCR sits 37% above its 52-week low of $3.625.
Summary
Lifecore Biomedical has signed a manufacturing services agreement with a new biopharmaceutical customer for an injectable ophthalmic product. This agreement covers process development and technical transfer, with commercial manufacturing anticipated upon regulatory approval. This marks the sixth addition to the company's late-stage pipeline in seven months. The news provides a positive counterpoint to the significant 34% year-over-year revenue decline reported in Q1 2026, demonstrating progress in securing future business and diversifying its customer base.
At the time of this announcement, LFCR was trading at $4.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $181.9M. The 52-week trading range was $3.63 to $8.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.